Applied Clinical Trials Direct
Having trouble viewing this e-mail? Click here.
  May 30, 2013
In This Edition
News Roundup: Streamlining IRB Documentation Processes
Articles: Negotiating Clinical Trial Agreements and Budgets
Blog Posts: Phase II/III Outsourcing Growth
Marketplace: Marketplace


News Roundup
bullet CTMS Streamlines Managing IRB Documentation
bullet Web Portal Survey: Access Studies Progress Through Single Portal
bullet CEL-SCI Expands Phase III Trial
bullet PharmaSeek Implements Allegro CTMS for Site Management


Articles
bullet GSK Vaccines Complements RBM with Intelligent Statistical Modeling Solution
bullet Negotiating Clinical Trial Agreements and Budgets with Sites


Blogs Posts
bullet Phase II/III Outsourcing Growth
bullet Europe Faces Gaps in International GCP Inspections

Sponsored
Find out which major CROs ranked highest among sites in the May issue of The CenterWatch Monthly!
More than 2,000+ respondents to CenterWatch’s Global Site Relationship Survey revealed that the effectiveness of CROs to manage working relationships with sites had slipped during the past two years with the average CRO falling below performance expectations. Comprehensive reports on individual results also available. Subscribe today

Marketplace

Sponsored
PRA has the local and regulatory knowledge, investigator relationships, expertise and experience to help you run a successful trial in a variety of emerging markets. www.praintl.com

Sponsored
Drive better early phase oncology decisions. Get to proof of concept as quickly and efficiently as possible without sacrificing quality.
Learn More

Sponsored
Enroll First-in-Man Patient Studies Quicker in Eastern Europe
Learn More

Sponsored
Which Imaging Core Lab has the most scientific experience and the best technology?
The merger of BioClinica and CoreLab Partners makes the answer clear.
Learn More

Sponsored
Drug Development Strategies in China
Pharma and biotech firms who are relative newcomers to the Chinese market aren't aware that the regulatory climate has changed dramatically in recent years. SFDA approval times for Clinical Trials Approvals have dropped to 7-9 months for small molecules. There are also opportunities in China for sponsors that have not yet completed Phase II trials to create a parallel approval strategy. Even without final details (like final dosing) it’s possible to file a CTA for Phase III based on the most current early phase results. This parallel submission strategy can shave several months off the final approval time in China. Learn More


Follow Us

Ask The Editor

Lisa Henderson
Editor in Chief [email protected]